B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

Breakthrough nanovaccine uses tumor cell membranes and immune-boosting polymers to enhance personalized cancer immunotherapy, ...

In tests with mice, a protein derived from the virus boosted the immune system's ability to kill cancer cells.

Neuro-immunological interactions have emerged as pivotal regulators of chronic-wound repair, integrating signals from the ...

You may have seen it in the news recently: a baby in Pennsylvania with a rare genetic disorder was healed with a personalized ...

At the heart of innovation is T-win®, a groundbreaking vaccine platform that could change how we treat cancer.

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

The herpes virus is an infection that often causes painful blisters on the mouth and or genitals. Interestingly, the viral ...

Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT ...

Recent studies reveal the herpes virus may enhance cancer treatment by activating T cell pathways, improving immunotherapy effectiveness against tumors.